Publication

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline

Journal Paper/Review - Dec 22, 2021

Units
Keywords
PubMed
Doi
Link
Contact

Citation
Daly M, Robinson C, Qin A, Phillips T, Patel J, Padda S, Moore A, Gubens M, Früh M, Detterbeck F, David E, Bradley J, Arenberg D, Antonoff M, Ismaila N, Singh N, Simone C. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol 2021:JCO2102528.
Project
Type
Journal Paper/Review (English)
Journal
J Clin Oncol 2021
Publication Date
Dec 22, 2021
Issn Print
Issn Electronic
1527-7755
Pages
JCO2102528
Publisher
Brief description/objective

PURPOSE
To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non-small-cell lung cancer (NSCLC).

METHODS
An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, community oncology, research methodology, and advocacy experts was convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2021. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.

RESULTS
The literature search identified 127 relevant studies to inform the evidence base for this guideline.

RECOMMENDATIONS
Evidence-based recommendations were developed to address evaluation and staging workup of patients with suspected stage III NSCLC, surgical management, neoadjuvant and adjuvant approaches, and management of patients with unresectable stage III NSCLC.Additional information is available at www.asco.org/thoracic-cancer-guidelines.